Literature DB >> 20816928

Influence of size and surface roughness of large lactose carrier particles in dry powder inhaler formulations.

Martin J Donovan1, Hugh D C Smyth.   

Abstract

The objective of this study was to determine the effect of both carrier particle size and surface roughness on the aerosol performance of dry powder formulations. Two morphologically distinct grades of lactose, anhydrous (AN) and granulated (GR), were fractionated into 11 discreet sizes up to 300μm, and separately employed as carriers in 2% (w/w) budesonide blends. In vitro deposition studies were performed at 60Lmin(-1) with an Aerolizer(®) DPI. It was found that large carriers can improve dispersion performance, although the effect is more pronounced with greater surface roughness. AN carriers exhibited minimal surface roughness and generally behaved as predicted from the literature, with the smaller carriers outperforming their larger counterparts. In contrast, GR carriers had a high degree of surface roughness, and the dispersion performance of larger carriers exceeded that of the smaller size fractions. Comparing the two lactose grades, AN carriers deposited a greater fraction of the total dose up to the 90-125μm size range, when they were surpassed in performance by the GR carriers. These results suggest that the mechanism of drug detachment varies with the physical properties of the carrier particle population, where surface roughness can alter the predominant detachment mechanism to favor larger carrier particle diameters. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20816928     DOI: 10.1016/j.ijpharm.2010.08.045

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  16 in total

1.  Effects of device and formulation on in vitro performance of dry powder inhalers.

Authors:  Wallace P Adams; Sau L Lee; Robert Plourde; Robert A Lionberger; Craig M Bertha; William H Doub; Jean-Marc Bovet; Anthony J Hickey
Journal:  AAPS J       Date:  2012-04-05       Impact factor: 4.009

2.  Preparation and in vitro aerosol performance of spray-dried Shuang-Huang-Lian corrugated particles in carrier-based dry powder inhalers.

Authors:  Jing-Jing Yang; Chun-Yu Liu; Li-Hui Quan; Yong-Hong Liao
Journal:  AAPS PharmSciTech       Date:  2012-05-30       Impact factor: 3.246

3.  Multi-scale modelling of powder dispersion in a carrier-based inhalation system.

Authors:  Zhenbo Tong; Hidehiro Kamiya; Aibing Yu; Hak-Kim Chan; Runyu Yang
Journal:  Pharm Res       Date:  2014-12-17       Impact factor: 4.200

4.  Engineered mannitol ternary additives improve dispersion of lactose-salbutamol sulphate dry powder inhalations.

Authors:  Waseem Kaialy; Ali Nokhodchi
Journal:  AAPS J       Date:  2013-04-17       Impact factor: 4.009

5.  The effect of engineered mannitol-lactose mixture on dry powder inhaler performance.

Authors:  Waseem Kaialy; Hassan Larhrib; Gary P Martin; Ali Nokhodchi
Journal:  Pharm Res       Date:  2012-04-05       Impact factor: 4.200

6.  Freeze-dried mannitol for superior pulmonary drug delivery via dry powder inhaler.

Authors:  Waseem Kaialy; Ali Nokhodchi
Journal:  Pharm Res       Date:  2012-10-16       Impact factor: 4.200

7.  Evaluation of granulated lactose as a carrier for DPI formulations 1: effect of granule size.

Authors:  Ping Du; Ju Du; Hugh D C Smyth
Journal:  AAPS PharmSciTech       Date:  2014-06-25       Impact factor: 3.246

8.  Improving Dry Powder Inhaler Performance by Surface Roughening of Lactose Carrier Particles.

Authors:  Bernice Mei Jin Tan; Lai Wah Chan; Paul Wan Sia Heng
Journal:  Pharm Res       Date:  2016-04-18       Impact factor: 4.200

9.  Development and comparison of new high-efficiency dry powder inhalers for carrier-free formulations.

Authors:  Srinivas R B Behara; P Worth Longest; Dale R Farkas; Michael Hindle
Journal:  J Pharm Sci       Date:  2013-12-04       Impact factor: 3.534

10.  Studies on the effect of the size of polycaprolactone microspheres for the dispersion of salbutamol sulfate from dry powder inhaler formulations.

Authors:  Rinku A Tuli; Graeme A George; Tim R Dargaville; Nazrul Islam
Journal:  Pharm Res       Date:  2012-05-15       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.